Literature DB >> 12119227

Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up.

Yüksel Peker1, Jan Hedner, Jeanette Norum, Holger Kraiczi, Jan Carlson.   

Abstract

The incidence of a cardiovascular disease (CVD) was explored in a consecutive sleep clinic cohort of 182 middle-aged men (mean age, 46.8 +/- 9.3; range, 30-69 years in 1991) with or without obstructive sleep apnea (OSA). All subjects were free of hypertension or other CVD, pulmonary disease, diabetes mellitus, psychiatric disorder, alcohol dependency, as well as malignancy at baseline. Data were collected via the Swedish Hospital Discharge Register covering a 7-year period before December 31, 1998, as well as questionnaires. Effectiveness of OSA treatment initiated during the period as well as age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP) at baseline, and smoking habits were controlled. The incidence of at least one CVD was observed in 22 of 60 (36.7%) cases with OSA (overnight oxygen desaturations of 30 or more) compared with in 8 of 122 (6.6%) subjects without OSA (p < 0.001). In a multiple logistic regression model, significant predictors of CVD incidence were OSA at baseline (odds ratio [OR] 4.9; 95% confidence interval [CI], 1.8-13.6) and age (OR 23.4; 95% CI, 2.7-197.5) after adjustment for BMI, SBP, and DBP at baseline. In the OSA group, CVD incidence was observed in 21 of 37 (56.8%) incompletely treated cases compared with in 1 of 15 (6.7%) efficiently treated subjects (p < 0.001). In a multiple regression analysis, efficient treatment was associated with a significant risk reduction for CVD incidence (OR 0.1; 95% CI, 0.0-0.7) after adjustment for age and SBP at baseline in the OSA subjects. We conclude that the risk of developing CVD is increased in middle-aged OSA subjects independently of age, BMI, SBP, DBP, and smoking. Furthermore, efficient treatment of OSA reduces the excess CVD risk and may be considered also in relatively mild OSA without regard to daytime sleepiness.

Entities:  

Mesh:

Year:  2002        PMID: 12119227     DOI: 10.1164/rccm.2105124

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  200 in total

Review 1.  Phosphinic peptides as zinc metalloproteinase inhibitors.

Authors:  V Dive; D Georgiadis; M Matziari; A Makaritis; F Beau; P Cuniasse; A Yiotakis
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

2.  Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials.

Authors:  G V Robinson; J C T Pepperell; H C Segal; R J O Davies; J R Stradling
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

3.  Accuracy and linearity of positive airway pressure devices: a technical bench testing study.

Authors:  Luis Torre-Bouscoulet; Elodia López-Escárcega; José Luis Carrillo-Alduenda; Fernando Arredondo-Del-Bosque; Margarita Reyes-Zúñiga; Armando Castorena-Maldonado
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

4.  CIH: from sleep apnea to breath-hold diving. Is sympathetic activation inevitable?

Authors:  Mark W Chapleau
Journal:  Clin Auton Res       Date:  2010-04       Impact factor: 4.435

5.  An official American Thoracic Society statement: continuous positive airway pressure adherence tracking systems. The optimal monitoring strategies and outcome measures in adults.

Authors:  Richard J Schwab; Safwan M Badr; Lawrence J Epstein; Peter C Gay; David Gozal; Malcolm Kohler; Patrick Lévy; Atul Malhotra; Barbara A Phillips; Ilene M Rosen; Kingman P Strohl; Patrick J Strollo; Edward M Weaver; Terri E Weaver
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

6.  Combined effect of obstructive sleep apnea and age on daytime blood pressure.

Authors:  Chun-Chih Chao; Jiunn-Liang Wu; Yu-Tuan Chang; Cheng-Yu Lin
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-15       Impact factor: 2.503

7.  Reactive oxygen species contribute to sleep apnea-induced hypertension in rats.

Authors:  Carmen M Troncoso Brindeiro; Ana Q da Silva; Kyan J Allahdadi; Victoria Youngblood; Nancy L Kanagy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-08-31       Impact factor: 4.733

8.  Effect of continuous positive airway pressure on day/night rhythm of prothrombotic markers in obstructive sleep apnea.

Authors:  Roland von Känel; Loki Natarajan; Sonia Ancoli-Israel; Paul J Mills; Tanya Wolfson; Anthony C Gamst; José S Loredo; Joel E Dimsdale
Journal:  Sleep Med       Date:  2012-10-01       Impact factor: 3.492

9.  Left ventricular morphology and systolic function in sleep-disordered breathing: the Sleep Heart Health Study.

Authors:  Hassan A Chami; Richard B Devereux; John S Gottdiener; Reena Mehra; Mary J Roman; Emelia J Benjamin; Daniel J Gottlieb
Journal:  Circulation       Date:  2008-05-05       Impact factor: 29.690

Review 10.  Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment.

Authors:  Corey J Leinum; John M Dopp; Barbara J Morgan
Journal:  Nutr Clin Pract       Date:  2009-12       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.